Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T/CAR-NK in R/R B-cell Lymphoma and B-ALL
NCT06596057Phase 1Active, not recruiting
- Sponsor
- Second Hospital of Shandong University
- Start
- Feb 2024
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in B cell lymphoma and B-cell acute lymphoblastic leukemia (B-ALL), sponsored by Second Hospital of Shandong University. Primary endpoints: Objective Response Rate at 6 months and Progression-Free Survival at 1 year. Started Feb 2024; status: active, not recruiting.
02
Conditions
B cell lymphomaB-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06596057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06596057.